Verona Pharma plc

Verona Pharma — Q2 2022 Earnings Presentation

15 slides from Verona Pharma's earnings presentation, Aug 9, 2022

  1. Slide 1: ENHANCE-2 Phase 3 data

    ENHANCE-2 Phase 3 data August 2022 Nasdaq: VRNA | www.veronapharma.com

  2. Slide 2: Forward-looking statements

    Forward-looking statements This presentation contains “forward‐looking” statements that are based on the beliefs and assumptions and on information currently available to management of Verona Pharma plc (together with its consolidated subsidiaries, the “Company”). All statements other than statement

  3. Slide 3: Agenda

    Agenda 3 On Today’s Call: • Welcome and ENHANCE-2 Data Overview David Zaccardelli, PharmD, CEO • Financial Review Mark Hahn, CFO • Q&A • Closing Remarks David Zaccardelli, PharmD, CEO Joining for Q&A: • Antonio Anzueto, MD Professor of Medicine and Section, Chief of Pulmonary at South Texas Veterans

  4. Slide 4: Pivotal Phase 3 program

    Pivotal Phase 3 program Two efficacy and safety studies: ENHANCE-1 and ENHANCE-2 4 Ensifentrine 3mg BID N=500 Placebo BID N=300 Ensifentrine as a Novel inHAled Nebulized COPD thErapy in moderate to severe COPD ENHANCE-1 N=800 ENHANCE-2 N=800 Ensifentrine 3mg BID N=500 Placebo BID N=300 Long-term saf

  5. Slide 5: ENHANCE-2 baseline characteristics

    ENHANCE-2 baseline characteristics Demographics and baseline characteristics well balanced between groups 5 Parameter Ensifentrine n=499 Placebo n=291 Total n=790 Age, mean (SD) 65.0 (7.4) 65.3 (7.3) 65.1 (7.4) Gender, % Male, n (%) 245 (49.1) 138 (47.4) 383 (48.5) Moderate / Severe COPD, n (%) Mild

  6. Slide 6: Primary endpoint met in Phase 3 ENHANCE-2

    6 -100 -50 0 50 100 150 0 1 2 3 4 5 6 7 8 9 10 11 12 FE V 1 m ea n c h an ge f ro m b as el in e, m L Time post dose, h Ensifentrine 3 mg placebo Primary endpoint met in Phase 3 ENHANCE-2 Significant and clinically meaningful improvements in lung function at Week 12 N=789 Ensifentrine 3 mg placebo +

  7. Slide 7: Ensifentrine improves lung function in all subgroups

    Ensifentrine improves lung function in all subgroups Statistically significant improvements versus placebo in all subgroups (All p < 0.05) 7 FE V 1 m e an c h an ge f ro m b as e lin e , m L 0 20 40 60 80 100 120 140 160 Average FEV1 AUC 0-12h post-dose at Week 12 by Subgroup Phase 3 ENHANCE-2 data

  8. Slide 8: Ensifentrine reduces exacerbation rate

    8 Ensifentrine reduces exacerbation rate 42% reduction in rate of moderate or severe COPD exacerbation vs placebo Treatment Annualized Event Rate LS mean, (95% CI) Rate Ratio (95% CI) Exacerbation Rate Reduction p-value Ensifentrine 3 mg (n = 498) 0.24 (0.18, 0.33) 0.58 (0.39, 0.88) 42% 0.0109 Place

  9. Slide 9: Ensifentrine significantly delays time to first exacerbation

    Ensifentrine significantly delays time to first exacerbation 9 42% reduction in risk of a COPD exacerbation Ensifentrine vs. Placebo (N = 789) Hazard Ratio (95%, CI) 0.58 (0.38, 0.87) Risk Reduction 42% P-value 0.0088 498 481 443 422 399 390 278 291 275 257 232 218 201 151 Number at risk Phase 3 ENH

  10. Slide 10: Ensifentrine showed improvement in symptoms and QOL

    Ensifentrine showed improvement in symptoms and QOL Progressive improvement in placebo impacted statistical significance 10 Symptoms E-RS Total Score by Week (units) (1) Minimal clinically important difference ***p ≤ 0.001 **p ≤ 0.01 *p ≤ 0.05 -2.5 -2.0 -1.5 -1.0 -0.5 0.0 Week 6 Week 12 Week 24 MCID

  11. Slide 11: Adverse events similar to placebo

    • Cardiovascular: 11 (2.2%) on ensifentrine; 13 (4.5%) on placebo • Gastrointestinal Disorders: 26 (5.2%) on ensifentrine; 15 (5.2%) on placebo • Pneumonia: 3 (0.6%) on ensifentrine; 5 (1.7%) on placebo Adverse events similar to placebo TEAE: treatment-emergent adverse event11 Event Ensifentrine 3 m

  12. Slide 12: ENHANCE-2 top-line summary

    ENHANCE-2 top-line summary • Data readout measures 12 Endpoint Top-line Measurement Data Primary endpoint (at Week 12) Average FEV1 AUC (0-12 hours) post dose +94 mL (p<0.0001) vs placebo Secondary endpoints (Lung function at Week 12) (Symptoms / QOL at Week 24) Peak FEV1 +146 mL (p<0.0001) vs place

  13. Slide 13: Financial Update

    Financial Update B Verona Pharma Breath of Innovation®

  14. Slide 14: Q2 2022 financial results

    Q2 2022 financial results ($ thousands) Cash runway through at least 2023* 14 Statements of Operations Q2 2022 Q2 2021 Research and development 14,982 20,563 Selling, general and administrative 5,526 7,985 Total operating expenses $20,508 $28,548 Operating loss (20,508) (28,548) R&D tax credit 5,409

  15. Slide 15: Q&A

    Q&A Verona Pharma 1s Breath of Innovation®

Verona Pharma — Q2 2022 Earnings Presentation on 6ix